{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026063","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.421381+00:00","generated_at":"2026-05-26T04:48:28.743965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027","bullets":["Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.","Cash and marketable securities $241.0M as of Dec 31, 2024, sufficient into at least 2027.","Phase 1b PIONEER trial of pociredir in SCD: 10 patients enrolled in 12 mg cohort; data expected mid-2025.","Plan to submit IND for Diamond-Blackfan anemia program in Q4 2025.","Phase 3 REACH trial (losmapimod) data to be presented at MDA Conference on March 19, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026063","json":"https://secwatch.observer/filing/0000950170-25-026063.json","markdown":"https://secwatch.observer/filing/0000950170-25-026063.md","text":"https://secwatch.observer/filing/0000950170-25-026063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/0000950170-25-026063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/fulc-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:48:28.743965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}